Original ResearchPublished 12 October 2026Efficacy and safety of immune checkpoint inhibitor plus bevacizumab-based chemotherapy in advanced or recurrent KRAS -mutant non-squamous NSCLC: the SPIRAL-STONE studyMasaki Ishida · Tadaaki Yamada · Riko Kamada · Makoto Hibino · Masashi Egami · Takayuki Nakano · Tatsuya Imabayashi · Chieko Takumi · Koichi Ishida · Masafumi Takeshita · Ken Masubuchi · Miiru Izumi · Takayo Ota · Shoki Morito · Yusuke Chihara · Soichi Hirai · Shinsuke Shiotsu · Ryo Sawada · Hayato Kawachi · Naoya Nishioka · Masahiro Iwasaku · Koichi TakayamaFrontiers in Immunologydoi 10.3389/fimmu.2026.1875501
Systematic ReviewPublished 9 October 2026Comparative effectiveness and safety of almonertinib in EGFR-mutated non-small cell lung cancer: an integrated evidence synthesisBiaoxue Rong · Hui Pan · Tian Fu · Yanfeng Liu · Pan Yang · Jiaying Zhang · Ying WangFrontiers in Pharmacologydoi 10.3389/fphar.2026.1932051
Original ResearchPublished 9 October 2026Population cellular kinetics and exposure-CSR analysis of CAR-T cells in Chinese patients with relapsed/refractory B-ALLYicong Bian · Jinjie Yuan · Chenrong Huang · Kaijie Zhang · Ling Xue · Fan Xia · Liqing Kang · Yan Wang · Hua Zhang · Lei Yu · Depei Wu · Liyan MiaoFrontiers in Pharmacologydoi 10.3389/fphar.2026.1878984
Original ResearchPublished 6 October 2026Outcomes and prognostic factors in dogs with subcutaneous and intramuscular hemangiosarcoma treated with hypofractionated radiation therapy and chemotherapyAna Paula Rebelo · Adriana Furtado · Rance Sellon · Gregory D. Roberts · Janean FidelFrontiers in Veterinary Sciencedoi 10.3389/fvets.2026.1925779
Original ResearchPublished 29 September 2026NMA plus antitumor therapy versus antitumor therapy alone in patients with BCLC stage B or C hepatocellular carcinoma and pre-cachexia or cachexia: protocol for a prospective, multicenter, randomized, open-label phase II trialRuihong Dai · Facheng Lu · Weibing Leng · Qing He · Wenhao Guo · Tao Hai · Chang LiuFrontiers in Gastroenterologydoi 10.3389/fgstr.2026.1926294
ReviewPublished 25 September 2026CLDN18 and FGFR2 splicing variants are emerging tumor-associated antigens for cancer therapyMasuko Katoh · Masaru KatohFrontiers in Molecular Medicinedoi 10.3389/fmmed.2026.1927389
Systematic ReviewPublished 9 July 2026Comparative efficacy of subsequent-line therapies for advanced triple-negative breast cancer: a bayesian network meta-analysisZheng Xu · Linxian Ding · Tai Zhao · Zhoumin XuOncology Reviewsdoi 10.3389/or.2026.1834466
Systematic ReviewPublished 19 March 2026Meta-analysis of efficacy and safety of Yttrium-90 radioembolization (TARE) in the treatment of advanced hepatocellular carcinomaHongyin Lin · Quanhui TanFrontiers in Nuclear Medicinedoi 10.3389/fnume.2026.1784215
